{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.400","upperLimit":"4.05","value":"1.03"},{"groupId":"OG001","lowerLimit":"0.433","upperLimit":"4.08","value":"0.983"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"7"},{"groupId":"OG001","value":"7"}],"units":"Participants"}],"description":"The Tmax of relugolix was determined for single and repeat doses in subsets of participants from Japan. Single dose PK was assessed on Day 1 following an initial 360 mg dose of relugolix. Repeat dose PK was assessed following repeat dosing of relugolix 120 mg once daily for 2 weeks.","dispersionType":"Full Range","groups":[{"description":"Relugolix oral loading dose of 360 mg (3 x 120-mg tablets) on Day 1.","id":"OG000","title":"Relugolix Single-Dose"},{"description":"Relugolix 120-mg tablet administered orally once daily for 2 weeks following an oral loading dose of 360 mg (3 x 120-mg tablets) on Day 1.","id":"OG001","title":"Relugolix Repeat-Dose"}],"paramType":"MEDIAN","populationDescription":"A subset of Japanese participants enrolled in study were included in the PK analysis.","reportingStatus":"POSTED","timeFrame":"Predose and 0.5, 1, 2, 4, 6, 8, 12, and 24 hours postdose on Day 1 and Week 2","title":"Time To Maximum Observed Plasma Concentration (Tmax) Of Relugolix","type":"SECONDARY","unitOfMeasure":"hours"}